Canlyniadau Chwilio - Tai‐Tsang Chen

  • Dangos 1 - 13 canlyniadau o 13
Mireinio'r Canlyniadau
  1. 1
    Statistical issues and challenges in immuno-oncology

    Statistical issues and challenges in immuno-oncology gan Tai‐Tsang Chen

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors

    Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors gan Tai‐Tsang Chen

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

    Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study gan Neil P. Shah, Wang, Amit Roy, Andreas Hochhaus, Kantarjian, Tai‐Tsang Chen

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

    Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma gan Feng Yan, Amit Roy, Eric Masson, Tai‐Tsang Chen, Rachel Humphrey, Jeffrey S. Weber

    Cyhoeddwyd 2013
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)

    Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) gan David F. McDermott, John B.A.G. Haanen, Tai‐Tsang Chen, Paul Lorigan, Steven O’Day

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

    Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia gan Alfonso Quintás-Cardama, Jorge E. Cortés, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, David Liu, Eric Bleickardt, Tai‐Tsang Chen, Hagop M. Kantarjian

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma gan Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra A. Patt, Tai‐Tsang Chen, David M. Berman, Jedd D. Wolchok

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

    Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial gan Michele Maio, Jean‐Jacques Grob, Steinar Aamdal, Igor Bondarenko, Caroline Robert, L. Thomas, Claus Garbe, Vanna Chiarion‐Sileni, Alessandro Testori, Tai‐Tsang Chen, Marina Tschaika, Jedd D. Wolchok

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective

    Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective gan Neil Lineberry, Jesse A. Berlin, Bernadette Mansi, Susan Glasser, Michael Berkwits, Christian Klem, Ananya Bhattacharya, Leslie Citrome, Robert E. Enck, John Fletcher, Daniel G. Haller, Tai‐Tsang Chen, Christine Lainé

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy

    Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy gan Stefan Suciu, Alexander M.M. Eggermont, Paul Lorigan, John M. Kirkwood, Svetomir N. Markovic, Claus Garbe, David Cameron, Srividya Kotapati, Tai‐Tsang Chen, Keith Wheatley, Natalie Ives, Gaetan de Schaetzen, Achmad Efendi, Marc Buyse

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias gan Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Ron Paquette, Jorge E. Cortés, Susan O’Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath R. Iyer, Tai‐Tsang Chen, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers

    Cyhoeddwyd 2006
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

    Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358 gan R. Wendel Naumann, Ana Oaknin, Tim Meyer, José M. López-Picazo, Christopher D. Lao, Yu Jeong Bang, Valentina Boni, William H. Sharfman, J.C. Park, Lot A. Devriese, Kenichi Harano, Christine H. Chung, Suzanne L. Topalian, Kam Zaki, Tai‐Tsang Chen, Junchen Gu, B. Li, Adam Barrows, Andrea Horváth, Kathleen N. Moore

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma gan Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: